Abstract: Metabolic dysfunction associated fatty liver disease (MAFLD) and metabolic dysfunction associated steatohepatitis (MASH) are intrinsically linked to the cardiovascular system,kidney,and other organs through complex pathophysiological mechanisms.Metabolic abnormalities constitute the most pivotal common basis between MAFLD/MASH and chronic kidney disease (CKD),while the polymorphisms of multiple genes and the gut⁃liver⁃kidney axis also play important roles in disease initiation and progression.MASH is closely linked to the cardiovascular⁃kidney⁃metabolic (CKM) syndrome.In this context,multidisciplinary teamwork is required to design individualized diet and exercise plans,and to use renin⁃angiotensin system inhibitors (RASi),sodium⁃glucose cotransporter⁃2 inhibitors (SGLT2i),glucagon⁃like peptide⁃1 receptor agonists (GLP⁃1RA),and finerenone in an evidence⁃based manner,thereby reducing hepatic inflammation and improving both cardiac and renal function.